- Home
- ATXS vs BALY Comparison
ATXS vs BALY Comparison
Compare ATXS & BALY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- BALY
- Stock Information
- Founded
- ATXS 2008
- BALY 2004
- Country
- ATXS United States
- BALY United States
- Employees
- ATXS N/A
- BALY N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- BALY Hotels/Resorts
- Sector
- ATXS Health Care
- BALY Consumer Discretionary
- Exchange
- ATXS Nasdaq
- BALY Nasdaq
- Market Cap
- ATXS 669.8M
- BALY 709.6M
- IPO Year
- ATXS 2015
- BALY N/A
- Fundamental
- Price
- ATXS $9.37
- BALY $17.80
- Analyst Decision
- ATXS Strong Buy
- BALY Hold
- Analyst Count
- ATXS 5
- BALY 7
- Target Price
- ATXS $25.60
- BALY $18.00
- AVG Volume (30 Days)
- ATXS 219.2K
- BALY 457.4K
- Earning Date
- ATXS 11-13-2024
- BALY 11-06-2024
- Dividend Yield
- ATXS N/A
- BALY N/A
- EPS Growth
- ATXS N/A
- BALY N/A
- EPS
- ATXS N/A
- BALY N/A
- Revenue
- ATXS N/A
- BALY $2,481,783,000.00
- Revenue This Year
- ATXS N/A
- BALY $3.55
- Revenue Next Year
- ATXS N/A
- BALY $1.38
- P/E Ratio
- ATXS N/A
- BALY N/A
- Revenue Growth
- ATXS N/A
- BALY 2.80
- 52 Week Low
- ATXS $4.26
- BALY $9.74
- 52 Week High
- ATXS $16.90
- BALY $18.00
- Technical
- Relative Strength Index (RSI)
- ATXS 30.44
- BALY 71.13
- Support Level
- ATXS $11.40
- BALY $17.76
- Resistance Level
- ATXS $11.75
- BALY $17.97
- Average True Range (ATR)
- ATXS 0.75
- BALY 0.10
- MACD
- ATXS -0.23
- BALY 0.02
- Stochastic Oscillator
- ATXS 7.64
- BALY 71.31
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About BALY Bally's Corporation
Ballys Corp is a casino entertainment company with a growing omni-channel presence. It currently owns and manages 15 casinos across 10 states, a golf course in New York, a horse racetrack in Colorado, and has access to OSB licenses in 18 states. It also owns Bally's Interactive International, formerly Gamesys Group, a online gaming operator, Bally Bet, a sports betting platform, and Bally Casino, a iCasino platform. The Company's casino operations include approximately 15,300 slot machines, 580 table games, and 3,800 hotel rooms.